Xiamen Amoytop Biotech Co Ltd

688278 · SHG · Healthcare / Biotechnology

42.71CNY-1.14 (-2.60%)

Price History

Full chart

Market Stats

Previous Close43.85

Open43.70

Day Range42.45 – 44.08

52-Week Range48.88 – 89.65

Volume1.73M

Market Cap21.59B

P/E (TTM)20.11

Forward P/E0.00

EPS2.63

Dividend Yield1.17%

Beta-0.17

50-Day Avg56.68

200-Day Avg63.71

About

Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China and internationally. It offers various drug products, including pegsomatropin injection, pegfilgrastim injection, molgramostim, filgrastim, and oprelvekin; active pharmaceutical ingredients (APIs); and reagents to treat viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is headquartered in Xiamen, China.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMr. Li Sun
Employees3.64K
HeadquartersNo. 330 Wengjiao Road, Xiamen, China, 361028, China
Websitehttps://www.amoytop.com

Leadership

Mr. Li SunChairman & GM · b. 1966
Ms. Yiling YangCFO, Accounting Supervisor, Deputy GM & Secretary · b. 1975
Ms. Liping LaiDeputy GM & Employee Representative Director · b. 1971
Mr. Jiehua ZhengDeputy General Manager · b. 1980
Mr. Weidong ZhouDeputy General Manager · b. 1971
Mr. Linzhong ZhangDeputy General Manager · b. 1969
Ms. Meihua YangDeputy General Manager · b. 1972
Ms. Liyu ShiDeputy General Manager · b. 1980

Financials

Income Statement

Currency: CNY	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	280.37M	323.08M	448.28M	729.67M	793.93M	1.13B	1.53B	2.10B	2.82B	3.70B
Growth (%)	-	+15.23%	+38.75%	+62.77%	+8.81%	+42.61%	+34.86%	+37.55%	+34.13%	+31.18%
Cost of Revenue	32.16M	42.87M	58.36M	81.74M	85.65M	126.99M	171.01M	140.20M	184.47M	259.99M
Gross Profit	248.21M	280.21M	389.93M	647.93M	708.29M	1.01B	1.36B	1.96B	2.63B	3.70B
Gross Margin	88.53%	86.73%	86.98%	88.80%	89.21%	88.78%	88.80%	93.32%	93.45%	100.00%
Operating Expense	218.24M	270.17M	355.21M	531.86M	550.15M	756.71M	948.97M	1.28B	1.66B	2.44B
Operating Income	29.97M	10.05M	34.72M	116.07M	158.14M	248.53M	406.92M	680.72M	970.74M	1.25B
Operating Margin	10.69%	3.11%	7.74%	15.91%	19.92%	21.95%	26.65%	32.41%	34.46%	33.92%
EBITDA	55.27M	39.56M	60.24M	137.30M	179.92M	255.27M	399.96M	694.80M	991.06M	1.24B
EBITDA Margin	19.71%	12.24%	13.44%	18.82%	22.66%	22.55%	26.19%	33.08%	35.18%	33.49%
Net Income	29.31M	5.17M	16.00M	64.29M	116.57M	181.20M	287.02M	555.45M	827.60M	1.04B
Net Income Margin	10.46%	1.60%	3.57%	8.81%	14.68%	16.00%	18.80%	26.45%	29.38%	28.08%
R&D	9.83M	19.67M	40.61M	53.41M	76.68M	81.51M	142.65M	229.98M	294.71M	388.03M
R&D as % of Total Revenue	3.50%	6.09%	9.06%	7.32%	9.66%	7.20%	9.34%	10.95%	10.46%	10.50%
Interest Expense	5.39M	6.45M	8.42M	8.51M	2.69M	1.29M	867.95K	784.07K	647.60K	1.42M
Interest Expense % of Total Revenue	1.92%	2.00%	1.88%	1.17%	0.34%	0.11%	0.06%	0.04%	0.02%	0.04%

Balance Sheet

Currency: CNY	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	642.58M	637.12M	707.77M	789.83M	1.19B	1.42B	1.77B	2.36B	3.05B	4.37B
Total Liabilities	164.49M	153.86M	208.51M	226.27M	192.33M	262.91M	360.96M	479.69M	497.10M	-3.01B
Total Equity	478.09M	483.26M	499.26M	563.55M	1.00B	1.16B	1.41B	1.88B	2.55B	3.01B
Cash	134.66M	83.82M	145.06M	205.89M	197.16M	285.42M	301.24M	412.96M	371.82M	553.16M
Total Debt	88.22M	80.00M	70.00M	60.09M	18.92M	25.16M	9.74M	7.92M	3.27M	-
Net Debt	-46.44M	-3.82M	-75.06M	-145.79M	-178.25M	-260.25M	-291.50M	-405.03M	-368.55M	-

Cash Flow

Currency: CNY	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	42.43M	-11.41M	89.15M	123.30M	92.61M	234.78M	363.16M	512.10M	430.63M	729.38M
Investing Cash Flow	-85.94M	-26.89M	-14.55M	-44.73M	-381.99M	-111.84M	-289.40M	-305.76M	-308.62M	-
Financing Cash Flow	126.42M	-12.29M	-13.76M	-17.86M	281.11M	-34.20M	-58.37M	-92.91M	-173.02M	-
Capital Expenditure	87.03M	26.89M	14.60M	44.83M	118.81M	190.93M	219.17M	288.46M	251.35M	256.14M
Free Cash Flow	-44.60M	-38.30M	74.55M	78.48M	-26.20M	43.85M	143.99M	223.64M	179.28M	473.23M
Dividends Paid	4.54M	4.02M	3.76M	3.39M	10.17M	20.34M	40.68M	86.65M	166.79M	252.87M
FCF to OCF	-105.13%	335.78%	83.62%	63.65%	-28.29%	18.68%	39.65%	43.67%	41.63%	64.88%
Dividend Paid to FCF	-10.18%	-10.51%	5.04%	4.32%	-38.81%	46.38%	28.25%	38.74%	93.03%	53.44%

Earnings

Report Date	Nov 29, 2019	Feb 28, 2020	Apr 21, 2020	Aug 17, 2020	Oct 27, 2020	Mar 30, 2021	Apr 26, 2021	Aug 25, 2021	Oct 28, 2021	Mar 30, 2022	Apr 27, 2022	Aug 18, 2022	Oct 25, 2022	Mar 30, 2023	Apr 24, 2023	Aug 17, 2023	Oct 24, 2024	Feb 25, 2025	Aug 20, 2025	Oct 22, 2025	Mar 26, 2026	Aug 18, 2026
EPS Estimate	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.56	0.56	0.57	0.82	0.80	0.65
EPS Actual	0.07	0.06	0.06	0.06	0.07	0.10	0.08	0.09	0.14	0.14	0.14	0.19	0.16	0.21	0.21	0.29	0.61	0.60	0.59	0.60	0.96	0.80
Surprise	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8.93%	7.14%	3.51%	-26.83%	20.00%	23.08%
Timing	After-hours	After-hours	After-hours	Pre-market	After-hours	After-hours	-	-	-	After-hours	After-hours	Pre-market	After-hours	Pre-market	After-hours	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market

Key Statistics & Ratios

Market Cap21.59B

Enterprise Value21.50B

Trailing P/E20.11

Forward P/E0.00

Price / Sales5.37

Price / Book6.98

EPS2.63

Book Value7.81

Revenue (TTM)4.02B

Gross Profit (TTM)3.66B

EBITDA1.42B

Profit Margin26.85%

Operating Margin34.86%

Return on Equity36.86%

Return on Assets20.77%

Shares Outstanding408.19M

Shares Float151.54M

Beta-0.17

Dividend Yield1.17%

Dividend Rate0.62

Payout Ratio23.57%

Dividends

20231×

0.21May 19, 2023

20221×

0.10May 24, 2022

20211×

0.05May 26, 2021

20201×

0.03Jun 4, 2020